It's unclear how many people in the US and abroad will get access to the powerful new HIV prevention medication ...

The US Food and Drug Administration (FDA) has approved Gilead Sciences’ Yeztug (lenacapavir), an injectable HIV-1 capsid inhibitor, for use as pre-exposure prophylaxis (PrEP) to reduce the risk of ...

Gilead's CEO says he's committed to making sure people around the world can get his firm's new HIV prevention shot Yeztugo.

The U.S. has approved the world's only twice-a-year shot to prevent HIV, the first step in an anticipated global rollout that ...

Individuals at risk for sexually-acquired HIV have a new injectable option for preexposure prophylaxis with the US Food and Drug Administration’s (FDA’s) approval of lenacapavir, according to a press ...

The US FDA has approved lenacapvir, sold under the brand name Yeztugo, as the first preventive treatment against HIV. It is a ...

The U.S. has approved the world’s only twice-a-year shot to prevent HIV, the first step in an anticipated global rollout that ...

Experts and advocates say that twice-a-year HIV PrEP injections have the prevention potential of a vaccine — and that a once-a-year version of lenacapavir would be even better. But will Yeztugo be ...

The Food and Drug Administration approved the first injectable HIV prevention medication, which could be a massive step forward in ending the long-term epidemic.

The U.S. FDA approved Gilead Sciences' lenacapavir, under the brand name Yeztugo, for HIV prevention. This twice-yearly ...